Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 14Other hematologic neoplasm 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

venetoclax 136Cytarabine 106Cyclophosphamide 104Specimen Handling 94fludarabine 86Azacitidine 84Biopsy 71Rituximab 45Methotrexate 42Daunorubicin 41fludarabine phosphate 40Vincristine 35Magnetic Resonance Spectroscopy 35Dexamethasone 35blinatumomab 31Injections 31Decitabine 31Granulocyte Colony-Stimulating Factor 29Mycophenolic Acid 28Whole-Body Irradiation 27Idarubicin 27ibrutinib 26Tacrolimus 26Prednisone 26Etoposide 26Busulfan 25Melphalan 24Doxorubicin 24acalabrutinib 23Calcium Dobesilate 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
tafasitamab × Other hematologic neoplasm × 90 days × Clear all
NCT07582159 2026-05-12

Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

City of Hope Medical Center

Phase 2 Not yet recruiting
35 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05718869 2026-05-08

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

City of Hope Medical Center

Phase 2 Active not recruiting
26 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡